Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis
Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis
复制标题
DOI：
10.1016/j.jaci.2010.06.031
复制
发表时间：
2010-12-01
影响因子：
14.2
通讯作者：
Fujieda, Shigeharu
中科院分区：
文献类型：
--
作者：
Makino, Yuka;Noguchi, Emiko;Fujieda, Shigeharu
背景：过敏性鼻炎是一个全球性的健康问题，在世界范围内引起重大疾病和残疾。过敏原特异性免疫疗法（SIT）是唯一可以改变过敏性疾病自然病程的治疗方法。然而，过敏原-SIT的确切机制还没有很好地understood.Objective：本研究的目的是确定蛋白质表达的签名反映过敏原-SIT-更具体地说，舌下免疫疗法（SLIT）.Methods：血清采取了两次从日本雪松引起的季节性变应性鼻炎患者：一次花粉季节之前，一次在季节。共有25例患者被随机分为安慰剂治疗组和活性药物治疗组。结果：共发现16种蛋白质在花粉季节差异表达。在差异表达的蛋白质中，SLIT治疗患者的补体C4 A、载脂蛋白A-IV（apoA-IV）和甲状腺素运载蛋白的血清水平显著升高，但安慰剂治疗患者的血清水平未升高。在这些蛋白质中，SLIT治疗患者的血清apoA-IV水平与临床药物治疗评分（r = -0.635; P <0.05）和生活质量评分（r = -0.516; P <0.05）相关。结论：本实验结果为SLIT治疗变应性鼻炎提供了新的思路和方法。（J Allergy Clin Immunol 2010;126：1163-9.）
Background: Allergic rhinitis is a global health problem that causes major illnesses and disability worldwide. Allergen-specific immunotherapy (SIT) is the only available treatment that can alter the natural course of allergic disease. However, the precise mechanism underlying allergen-SIT is not well understood.Objective: The aim of the current study was to identify protein expression signatures reflective of allergen-SIT-more specifically, sublingual immunotherapy (SLIT).Methods: Serum was taken twice from patients with seasonal allergic rhinitis caused by Japanese cedar: once before the pollen season and once during the season. A total of 25 patients was randomly categorized into a placebo-treated group and an active-treatment group. Their serum protein profiles were analyzed by 2-dimensional electrophoresis.Results: Sixteen proteins were found to be differentially expressed during the pollen season. Among the differentially expressed proteins, the serum levels of complement C4A, apolipoprotein A-IV (apoA-IV), and transthyretin were significantly increased in SLIT-treated patients but not in placebo-treated patients. Among these proteins, the serum levels of apoA-IV correlated with the clinical symptom-medication scores (r = -0.635; P < .05) and with quality of life scores (r = -0.516; P < .05) in the case of SLIT-treated patients. The amount of histamine released from the basophils in vitro was greatly reduced after the addition of recombinant apoA-IV in the medium (P < .01).Conclusion: Our data will increase the understanding of the mechanism of SLIT and may provide novel insights into the treatment of allergic rhinitis. (J Allergy Clin Immunol 2010;126:1163-9.)